Search results for " Ep"

showing 10 items of 3258 documents

miR‐200c and phospho‐AKT as prognostic factors and mediators of osteosarcoma progression and lung metastasis

2016

Lung metastasis is the major cause of death in osteosarcoma patients. However, molecular mechanisms underlying this metastasis remain poorly understood. To identify key molecules related with pulmonary metastasis of pediatric osteosarcomas, we analyzed high-throughput miRNA expression in a cohort of 11 primary tumors and 15 lung metastases. Results were further validated with an independent cohort of 10 primary tumors and 6 metastases. In parallel, we performed immunohistochemical analysis of activated signaling pathways in 36 primary osteosarcomas. Only phospho-AKT associated with lower overall survival in primary tumors, supporting its role in osteosarcoma progression. CTNNB1 expression a…

0301 basic medicineOncologyMaleCancer ResearchmiR‐200cLung NeoplasmsCDH1MetastasisCohort Studies0302 clinical medicineCell MovementPhospho‐AKTPhosphorylationChildOsteosarcomabiologyGeneral MedicineArticlesCadherinsPrognosisPrimary tumorGene Expression Regulation Neoplasticmedicine.anatomical_structureLung metastasisOncology030220 oncology & carcinogenesisDisease ProgressionMolecular MedicineOsteosarcomaFemaleSignal Transductionmedicine.medical_specialtyAdolescentMesenchymal to epithelial transitionArticle03 medical and health sciencesYoung AdultAntigens CDInternal medicineCell Line TumormicroRNAGeneticsmedicineBiomarkers TumorHumansEpithelial–mesenchymal transitionCell ProliferationLungGene Expression ProfilingReproducibility of ResultsEpithelial CellsPediatric osteosarcomamedicine.diseaseSurvival AnalysisEnzyme ActivationMicroRNAs030104 developmental biologyTumor progressionbiology.proteinProto-Oncogene Proteins c-aktMolecular Oncology
researchProduct

Phase Ib study evaluating safety and clinical activity of the anti-HER3 antibody lumretuzumab combined with the anti-HER2 antibody pertuzumab and pac…

2018

Summary Purpose To investigate the safety and clinical activity of comprehensive human epidermal growth factor receptor (HER) family receptor inhibition using lumretuzumab (anti-HER3) and pertuzumab (anti-HER2) in combination with paclitaxel in patients with metastatic breast cancer (MBC). Methods This phase Ib study enrolled 35 MBC patients (first line or higher) with HER3-positive and HER2-low (immunohistochemistry 1+ to 2+ and in-situ hybridization negative) tumors. Patients received lumretuzumab (1000 mg in Cohort 1; 500 mg in Cohorts 2 and 3) plus pertuzumab (840 mg loading dose [LD] followed by 420 mg in Cohorts 1 and 2; 420 mg without LD in Cohort 3) every 3 weeks, plus paclitaxel (8…

0301 basic medicineOncologyMaleReceptor ErbB-3Receptor ErbB-2Medizinchemistry.chemical_compound0302 clinical medicineErbB3Phase I StudiesAntineoplastic Combined Chemotherapy ProtocolsMedicinePharmacology (medical)skin and connective tissue diseasesMiddle AgedMetastatic breast cancerMetastatic breast cancerDiarrheaOncologyPaclitaxel030220 oncology & carcinogenesisMarcadors bioquímicsCohortFemalePertuzumabmedicine.symptommedicine.drugAdultDiarrheamedicine.medical_specialtyLoperamidePaclitaxelMama -- Càncer -- TractamentAntineoplastic AgentsBreast NeoplasmsHypokalemiaAntibodies Monoclonal HumanizedLoading dosePolymorphism Single Nucleotide03 medical and health sciencesPhase IHuman epidermal growth factor receptor 3 (HER3)Internal medicineHumansAgedPharmacologyPertuzumabbusiness.industryBiomarkerLumretuzumabmedicine.disease030104 developmental biologychemistryHuman epidermal growth factor receptor 2 (HER2)businessHeregulin (HRG)
researchProduct

Target Therapies for Uterine Carcinosarcomas: Current Evidence and Future Perspectives

2017

Carcinosarcomas (CS) in gynecology are very infrequent and represent only 2–5% of uterine cancers. Despite surgical cytoreduction and subsequent chemotherapy being the primary treatment for uterine CS, the overall five-year survival rate is 30 ± 9% and recurrence is extremely common (50–80%). Due to the poor prognosis of CS, new strategies have been developed in the last few decades, targeting known dysfunctional molecular pathways for immunotherapy. In this paper, we aimed to gather the available evidence on the latest therapies for the treatment of CS. We performed a systematic review using the terms “uterine carcinosarcoma”, “uterine Malignant Mixed Müllerian Tumors”, “target therapies”,…

0301 basic medicineOncologyPathologyAngiogenesisCarcinosarcomas epigenetics genetics immunotherapy uterine cancer.medicine.medical_treatmentReviewEpigenesis Geneticlcsh:Chemistry0302 clinical medicineCarcinosarcomaAntibodies BispecificCarcinosarcomas Epigenetics Genetics Immunotherapy Uterine cancerMedicinegeneticsMolecular Targeted Therapylcsh:QH301-705.5Human Epidermal Growth Factor Receptor 2SpectroscopyNeovascularization PathologicGeneral MedicineEpithelial Cell Adhesion MoleculePrognosisComputer Science ApplicationsErbB ReceptorsSurvival Rate030220 oncology & carcinogenesisUterine NeoplasmsFemaleImmunotherapymedicine.medical_specialtyPoor prognosisMixed Tumor MullerianCatalysisuterine cancerInorganic Chemistry03 medical and health sciencesCancer stem cellInternal medicineBiomarkers TumorHumansTarget therapyPhysical and Theoretical ChemistrycarcinosarcomasMolecular BiologySurvival rateChemotherapyepigeneticsbusiness.industryOrganic ChemistryImmunotherapy030104 developmental biologylcsh:Biology (General)lcsh:QD1-999businessInternational Journal of Molecular Sciences
researchProduct

Worldwide comparison of ovarian cancer survival: Histological group and stage at diagnosis (CONCORD-2)

2016

Abstract Objective Ovarian cancer comprises several histological groups with widely differing levels of survival. We aimed to explore international variation in survival for each group to help interpret international differences in survival from all ovarian cancers combined. We also examined differences in stage-specific survival. Methods The CONCORD programme is the largest population-based study of global trends in cancer survival, including data from 60 countries for 695,932 women (aged 15–99years) diagnosed with ovarian cancer during 1995–2009. We defined six histological groups: type I epithelial, type II epithelial, germ cell, sex cord-stromal, other specific non-epithelial and non-sp…

0301 basic medicineOncologySettore MED/42 - Igiene Generale E Applicata0302 clinical medicinemorphology80 and overStage (cooking)Aged 80 and overOvarian Neoplasmseducation.field_of_studyepidemiology; histology; morphology; ovarian cancer; stage; survival; Adolescent; Adult; Aged; Aged 80 and over; Female; Humans; Middle Aged; Neoplasm Staging; Ovarian Neoplasms; Oncology; Obstetrics and GynecologyObstetrics and Gynecologyepidemiology; histology; morphology; ovarian cancer; stage; survivalMiddle AgedTransitional cell carcinomaovarian cancerOncology030220 oncology & carcinogenesisClear cell carcinomaepidemiologyFemaleHumanAdultmedicine.medical_specialtyAdolescentPopulationSocio-culturalesurvivalArticlehistology03 medical and health sciencesInternal medicinemedicineHumansovarian cancer epidemiology survival stage morphology histologyeducationepidemiology ; histology ; morphology ; ovarian cancer ; stage ; survivalCancer stagingAgedNeoplasm StagingGynecologybusiness.industryOvarian NeoplasmCancermedicine.diseasestageCancer registry030104 developmental biologyOvarian cancerbusiness
researchProduct

Resminostat plus sorafenib as second-line therapy of advanced hepatocellular carcinoma - The SHELTER study

2016

Background & Aims No established therapies for patients with hepatocellular carcinoma (HCC) and progression on first-line sorafenib treatment currently exist. This phase I/II trial investigated safety, pharmacokinetics and potential biomarkers of the histone deacetylase inhibitor resminostat and a combination therapy with resminostat and sorafenib. Methods Patients with HCC and radiologically confirmed progression on sorafenib were treated in an exploratory, multi-center, open-label, uncontrolled, non-randomized, parallel group phase I/II study. In the combination group (n=38) four dose levels ranged from daily 200 to 600mg resminostat plus 400 to 800mg sorafenib. The monotherapy group (n=1…

0301 basic medicineOncologySorafenibmedicine.medical_specialtyCombination therapymedicine.drug_classMedizinCancer epigeneticPharmacology03 medical and health scienceschemistry.chemical_compound0302 clinical medicineCancer epigeneticsResminostatInternal medicineClinical endpointmedicineCarcinomaneoplasmsEpigenetic treatmentFirst-in-man studyHistone deacetylase inhibitorHepatologybusiness.industryHistone deacetylase inhibitormedicine.diseasedigestive system diseases030104 developmental biologyZinc finger protein 64chemistryCancer epigenetics; Drug resistance; Epigenetic treatment; Histone deacetylase inhibitor; Zinc finger protein 64030220 oncology & carcinogenesisHepatocellular carcinomaDrug resistancebusinessmedicine.drug
researchProduct

Current molecular and clinical insights into uveal melanoma (Review)

2021

Uveal melanoma (UM) represents the most prominent primary eye cancer in adults. With an incidence of approximately 5 cases per million individuals annually in the United States, UM could be considered a relatively rare cancer. The 90.95% of UM cases arise from the choroid. Diagnosis is based mainly on a clinical examination and ancillary tests, with ocular ultrasonography being of greatest value. Differential diagnosis can prove challenging in the case of indeterminate choroidal lesions and, sometimes, monitoring for documented growth may be the proper approach. Fine needle aspiration biopsy tends to be performed with a prognostic purpose, often in combination with radiotherapy. Gene expres…

0301 basic medicineOncologyUveal NeoplasmsCancer Researchmedicine.medical_specialtydiagnosisEnucleationBiology03 medical and health sciences0302 clinical medicineInternal medicinemedicineHumansNeoplasm MetastasisGrading (tumors)MelanomaBiomarkers; Diagnosis; Epigenetics; Prognosis; Staging; Treatment; Uveal melanomamedicine.diagnostic_testtreatmentepigeneticsMelanomaGene Expression ProfilingCancerbiomarkersArticlesstagingmedicine.diseasePrognosisPrimary tumor030104 developmental biologyFine-needle aspirationOncology030220 oncology & carcinogenesisMutationDifferential diagnosisuveal melanomaGNAQ
researchProduct

Imaging biomarkers of behavioral impairments: A pilot micro-positron emission tomographic study in a rat electrical post-status epilepticus model.

2018

Objective In patients with epilepsy, psychiatric comorbidities can significantly affect the disease course and quality of life. Detecting and recognizing these comorbidities is central in determining an optimal treatment plan. One promising tool in detecting biomarkers for psychiatric comorbidities in epilepsy is positron emission tomography (PET). Methods Results Behavioral and biochemical variables were cross-correlated with the results from two mu PET scans using the tracers [F-18]fluoro-2-deoxy-D-glucose ([F-18]FDG) and 2 '-methoxyphenyl-(N-2 '-pyridinyl)-p-F-18-fluoro-benzamidoethylpiperazine ([F-18]MPPF) to explore potential biomarkers for neurobehavioral comorbidities in an electrica…

0301 basic medicineOncologymedicine.medical_specialtyImaging biomarkerStatus epilepticusHippocampal formationAnxietyHippocampusPositron emission tomographicNesting BehaviorRats Sprague-Dawley03 medical and health scienceschemistry.chemical_compoundEpilepsySeverity assessment0302 clinical medicineStatus EpilepticusFluorodeoxyglucose F18Internal medicinepsychiatric comorbiditieMedicineAnimalsSocial BehaviorElectroshockmedicine.diagnostic_testbusiness.industryanimal modelmedicine.diseaseElectrodes ImplantedRats030104 developmental biologyNeurologychemistryPositron emission tomographyPositron-Emission TomographyepilepsyFemale[18F]MPPFNeurology (clinical)[18F]FDGMPPFmedicine.symptomRadiopharmaceuticalsbusiness030217 neurology & neurosurgeryBiomarkersEpilepsia
researchProduct

Epigenomic landscape of human colorectal cancer unveils an aberrant core of pan-cancer enhancers orchestrated by YAP/TAZ

2021

Cancer is characterized by pervasive epigenetic alterations with enhancer dysfunction orchestrating the aberrant cancer transcriptional programs and transcriptional dependencies. Here, we epigenetically characterize human colorectal cancer (CRC) using de novo chromatin state discovery on a library of different patient-derived organoids. By exploring this resource, we unveil a tumor-specific deregulated enhancerome that is cancer cell-intrinsic and independent of interpatient heterogeneity. We show that the transcriptional coactivators YAP/TAZ act as key regulators of the conserved CRC gained enhancers. The same YAP/TAZ-bound enhancers display active chromatin profiles across diverse human t…

0301 basic medicineOrganoidEpigenomicsTranscription FactorGeneral Physics and AstronomyColorectal NeoplasmAdaptor Proteins Signal Transducing; Colorectal Neoplasms; Gene Expression Regulation Neoplastic; Histone Code; Humans; Models Genetic; Organoids; RNA-Seq; Single-Cell Analysis; Trans-Activators; Transcription Factors; Tumor Cells Cultured; Enhancer Elements Genetic; Epigenesis GeneticEpigenesis Genetic0302 clinical medicineModelsAdaptor Proteins Signal Transducing Colorectal Neoplasms Gene Expression Regulation NeoplasticHistone Code Humans Models Genetic Organoids RNA-Seq Single-Cell Analysis Trans-Activators Transcription Factors Tumor Cells Cultured Enhancer Elements Genetic Epigenesis GeneticTumor Cells CulturedCancer genomicsHistone codeRNA-SeqEpigenomicsAdaptor Proteins Signal Transducing; Colorectal Neoplasms; Gene Expression Regulation Neoplastic; Histone Code; Humans; Models Genetic; Organoids; RNA-Seq; Single-Cell Analysis; Trans-Activators; Transcription Factors; Transcriptional Coactivator with PDZ-Binding Motif Proteins; Tumor Cells Cultured; YAP-Signaling Proteins; Enhancer Elements Genetic; Epigenesis GeneticMultidisciplinaryCulturedQAdaptor Proteins3. Good healthChromatinTumor CellsGene Expression Regulation NeoplasticHistone CodeOrganoidsSingle-Cell AnalysiEnhancer Elements GeneticTrans-Activator030220 oncology & carcinogenesisSingle-Cell AnalysisColorectal NeoplasmsHumanEnhancer ElementsScienceTumour heterogeneityBiologyGeneral Biochemistry Genetics and Molecular BiologyArticle03 medical and health sciencesGeneticmedicineHumansEpigeneticsEnhancerTranscription factorAdaptor Proteins Signal TransducingNeoplasticModels GeneticSignal TransducingCancerYAP-Signaling ProteinsGeneral Chemistrymedicine.diseaseColorectal cancerdigestive system diseases030104 developmental biologyGene Expression RegulationTranscriptional Coactivator with PDZ-Binding Motif ProteinsCancer cellCancer researchTrans-ActivatorsEpigenesisTranscription Factors
researchProduct

Elongated styloid process: An epidemiological study on digital panoramic radiographs

2017

Background The styloid process is a projecton of the temporal bone, its lenght is between 20 to 30 mm, when it is longer than 30 mm it is defined elongated styloid process. The aim of this study is an epidemiological evaluation of 1003 digital panoramic radiographs in an Italian population between 5 and 90 years old. Material and methods This is a retrospective analysis and the radiographs were selected from the Complex Operating Unit of Dentistry of Padua University Hospital database. The radiographs were performed using a Sirona Ortophos XG and the styloid process length was measured using the measuring tool of Sidexis Software. It was measured from the point where it left the temporal bo…

0301 basic medicinePanoramic radiographEpidemiological studyPanoramic radiographRadiographyEagle's syndrome; Elongated styloid process; Epidemiological study; Panoramic radiograph; Dentistry (all)03 medical and health sciences0302 clinical medicineTemporal boneRetrospective analysisMedicineGeneral DentistryProcess (anatomy)OrthodonticsEagle's syndromeOral Medicine and Pathologybusiness.industryResearch030206 dentistry:CIENCIAS MÉDICAS [UNESCO]Elongated styloid processUniversity hospitalItalian populationUNESCO::CIENCIAS MÉDICASDentistry (all)030101 anatomy & morphologybusinessJournal of Clinical and Experimental Dentistry
researchProduct

The Impacts of Tumor and Tumor Associated Epilepsy on Subcortical Brain Structures and Long Distance Connectivity in Patients With Low Grade Glioma

2018

Low grade gliomas in cerebral cortex often cause symptoms related to higher cerebral functions such as attention, memory and executive function before treatment is initiated. Interestingly, focal tumors residing in one cortical region can lead to a diverse range of symptoms, indicating that the impact of a tumor is extended to multiple brain regions. We hypothesize that the presence of focal glioma in the cerebral cortex leads to alterations of distant subcortical areas and essential white matter tracts. In this study, we analyzed diffusion tensor imaging scans in glioma patients to study the effect of glioma on subcortical gray matter nuclei and long-distance connectivity. We found that th…

0301 basic medicinePathologymedicine.medical_specialtyBrain tumorlcsh:RC346-429White matter03 medical and health sciences0302 clinical medicinegliomaGliomamedicinelcsh:Neurology. Diseases of the nervous systemOriginal Researchtumor associated epilepsybusiness.industrydiffusion tensor imagingmedicine.diseaseSubcortical gray matter030104 developmental biologymedicine.anatomical_structureNeurologyCerebral cortexconnectivityCerebellar cortexNeurology (clinical)business030217 neurology & neurosurgeryMRIDiffusion MRITractography
researchProduct